Tecentriq, Avastin Regimen Beats Anti-PD-L1 Monotherapy in MMR-Deficient, MSI-High Colorectal Cancer
Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...
Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...
In patients with high PD-L1 expression identified before surgery, clinicians should consider the possibility of lymph node metastasis when determining surgical strategy, including the extent of lymph ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback